

CLAIMS

*Sub. +
add D3
C35*

1. A vaccine formulation for nasal administration wherein the components are (a) a surface antigen from virus and (b) one or more vaccine antigens synergizing in adjuvant effect with (a), the antigen concentrations is in the range up to 1 mg each, preservatives and stabilizers can be added.

2. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is an antigen of viral nucleocapsid.

10 3. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigen of Hepatitis B Virus.

4. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Human Papilloma-Virus.

15 5. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Hepatitis C Virus.

6. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is a vaccine antigen of any nature or a mixture of different antigens receiving an immuno-enhancing effect from Hepatitis B surface antigen.

20 7. A vaccine formulation according to claims 1-6, administrated as a solid, liquid or spray product.

8. A vaccine formulation according to claims 1-6 for mucosal administration.

25 9. A vaccine formulation according to claims 1-6 for use as a therapeutic vaccine.

10. A vaccine formulation according to claims 1-6 for use as a preventive vaccine.

*add A1
add C07
51*

0 10 20 30 40 50 60 70 80 90